Topics:
Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Leukemia • CML • Hematology
Do you switch from imatinib to another TKI in patients with chronic phase CML who develop renal insufficiency?
There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?
Answer from: Medical Oncologist at Community Practice
Imatinib has been associated with a decline in GFR. It is not certain (and probably doubtful) that this represents kidney damage. If no other causes can be identified, a change could be appropriate. Bosutinib has been associated with a similar decline so nilotinib or dasatinib might be better option...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I would definitely consider changing the TKI in a CP-CML patient who develops renal insufficiency for which no other cause has been identified, especially if the patient has a relatively recent diagnosis of CML (within a year) and is not achieving his/her hematologic or molecular milestones. I would...